Pioneer Surgical Technology receives FDA clearance to market nano-based bone graft substitute

September 4, 2008: Pioneer Surgical Technology has received 510(k) clearance from the US Food and Drug Administration (FDA) to market FortrOss, a novel bone graft substitute utilizing the power of nanotechnology for orthopaedic applications. The FortrOss bone void filler is a scaffold for the in-growth of new bone and other connective tissues, when superior bone regeneration is required.

“The FortrOss carrier is a collagen-based bioscaffold processed to provide an osteopromotive effect,” with a patented “E-Matrix “technology that provides an open structure for bone growth and repair, explained Ron Hill, VP of research and development at Pioneer. The osteoconductive matrix in FortrOss utilizes Pioneer’s nanOss technology and is designed to mimic the nanostructures inherent in boney tissue.

Pioneer’s president and CEO, Matthew Songer, stated that the Fortr0ss bone graft substitute is the result of work leveraging a pair of 2007 acquisitions: Angstrom Medica’s nan0ss material, and the osteopromotive scaffold technology of Encelle Inc.’s E-Matrix biopolymer, “to create the most advanced bone void filler on the market.”

Edward Ahn, VP of biomaterials at Pioneer, added that the nanOss hydroxyapatite in FortrOss “resembles the size, shape, and chemistry of native bone,” so that boney tissue “recognizes it as native tissue.” This “mimicry of native bone makes nanOss superior to other calcium phosphates on the market.”

FortrOss is expected to be US market released later this year.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.